Omega-3 fatty acids: Benefits for cardio-cerebro-vascular diseases

Atherosclerosis

Volumn 225, Issue 2, 2012, Pages 291-295

  Siegel, G ^a,b   Ermilov, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer dementia; Cardiovascular diseases; Omega 3 fatty acids; Stroke and subtypes

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OMEGA 3 FATTY ACID; THROMBOXANE A2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ARTERY OCCLUSION; BLOOD PRESSURE; BODY MASS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DIETARY INTAKE; FIBER; FISH; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPID COMPOSITION; LOW DRUG DOSE; MILD COGNITIVE IMPAIRMENT; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK;

ALZHEIMER DISEASE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CONSTRICTION, PATHOLOGIC; DEMENTIA, VASCULAR; DIET; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; INTRACRANIAL ARTERIAL DISEASES; NUTRITION POLICY; STROKE;

EID: 84869506068     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.006     Document Type: Note

References (68)

1. Koppe C., Rodríguez M., Winkler K., et al. Reduction of arteriosclerotic nanoplaque formation and size by n-3 fatty acids in patients after valvular defect operation. Forsch Komplementmed 2009, 16:237-245.
2. Daviglus M.L., Stamler J., Orencia A.J., et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997, 336:1046-1053.
3. Gissi-Prevenzione Investigators Dietary supplementation with omega-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
4. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
5. Leaf A., Kang J.X., Xiao Y.F., Billman G.E. Clinical prevention of sudden cardiac death by omega-3 polyunsaturated fatty acids and mechanisms of prevention of arrhythmias by omega-3 fish oils. Circulation 2003, 107:2646-2652.
6. Thies F., Garry J.M.C., Yaqoob P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361:477-485.
7. Harris W.S. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65:1645S-1654S.
8. Minihane A.M., Khan S., Leigh-Firbank E.C., et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000, 20:1990-1997.
9. Von Schacky C., Angerer P., Kothny W., Theisen K., Mudra H. The effect of dietary ω-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 130:554-562.
10. Christensen J.H., Skou H.A., Fog L., et al. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation 2001, 103:651-657.
11. Gil Á. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002, 56:388-396.
12. Calder P.C. Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. Braz J Med Biol Res 2003, 36:433-446.
13. 2-isoprostane excretion. Redox Rep 2000, 5:45-46.
14. Mabile L., Piolot A., Boulet L., et al. Moderate intake of n-3 fatty acids is associated with stable erythrocyte resistance to oxidative stress in hypertriglyceridemic subjects. Am J Clin Nutr 2001, 74:449-456.
15. Herrmann W., Biermann J., Kostner G.M. Comparison of effects of n-3 to n-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol 1995, 76:459-462.
16. Ando M., Sanaka T., Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999, 10:2177-2184.
17. Hu F.B., Bronner L., Willet W.C., et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002, 287:1815-1821.
18. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346:1113-1118.
19. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986, 314:488-500.
20. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
21. Glass C.K., Witztum J.L. Atherosclerosis: the road ahead. Cell 2001, 104:503-516.
22. Scholz M., Kraft H.G., Lingenhel A., et al. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet 1999, 7:169-178.
23. Sasaki S., Kuwahara N., Kunitomo K., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002, 89:386-389.
24. Ramharack R., Barkalow D., Spahr M.A. Dominant negative effect of TGF-β1 and TNF-α on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 1998, 18:984-990.
25. Tsimikas S., Lau H.K., Han K.-R., et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004, 109:3164-3170.
26. Vogel J.H.K., Bolling S.F., Costello R.B., et al. Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation. Task Force on clinical expert consensus documents. J Am Coll Cardiol 2005, 46:184-221.
27. Breslow J.L. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr 2006, 83:1477S-1482S.
28. Mozaffarian D., Wu J.H.Y. Omega-3 fatty acids and cardiovascular disease. Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
29. 2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study. J Lipid Res 2010, 51:1179-1185.
30. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
31. Din J.N., Newby D.E., Flapan A.D. Omega 3 fatty acids and cardiovascular disease - fishing for a natural treatment. BMJ 2004, 328:30-35.
32. Studer M., Briel M., Leimenstoll B., Glass T.R., Bucher H.C. Effect of different antilipidemic agents and diets on mortality. A systematic review. Arch Intern Med 2005, 165:725-730.
33. Hooper L., Thompson R.L., Harrison R.A., et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332:752-755.
34. Keli S.O., Feskens E.J.M., Kromhout D. Fish consumption and risk of stroke. The Zutphen study. Stroke 1994, 25:328-332.
35. Gillum R.F., Mussolino M.E., Madans J.H. The relationship between fish consumption and stroke incidence. The NHANES I epidemiologic follow-up study. Arch Intern Med 1996, 156:537-542.
36. Orencia A.J., Daviglus M.L., Dyer A.R., Shekelle R.B., Stamler J. Fish consumption and stroke in men. 30-Year findings of the Chicago Western Electric study. Stroke 1996, 27:204-209.
37. Iso H., Sato S., Umemura U., et al. Linoleic acid, other fatty acids, and the risk of stroke. Stroke 2002, 33:2086-2093.
38. Barberger-Gateau P., Letenneur L., Deschamps V., Pérès K., Dartigues J.-F., Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002, 325:932-933.
39. Morris M.C., Evans D.A., Bienias J.L., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003, 60:940-946.
40. He K., Song Y., Daviglus M.L., et al. Fish consumption and incidence of stroke. A meta-analysis of cohort studies. Stroke 2004, 35:1538-1542.
41. Gorelick P.B., Wong K.S., Bae H.-J., Pandey D.K. Large artery intracranial occlusive disease. A large worldwide burden but a relatively neglected frontier. Stroke 2008, 39:2396-2399.
42. Kurth T., Moore S.C., Gaziano J.M., et al. Healthy lifestyle and the risk of stroke in women. Arch Intern Med 2006, 166:1403-1409.
43. Tanaka K., Ishikawa Y., Yokoyama M., et al. For the JELIS Investigators, Japan. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients. Subanalysis of the JELIS trial. Stroke 2008, 39:2052-2058.
44. Lalancette-Hébert M., Julien C., Cordeau P., et al. Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. Stroke 2011, 42:2903-2909.
45. Larsson S.C., Virtamo J., Wolk A. Dietary fats and dietary cholesterol and risk of stroke in women. Atherosclerosis 2012, 221:282-286.
46. Kim Y.-J., Kim O.Y., Cho Y., et al. Plasma phospholipid fatty acid composition in ischemic stroke: importance of docosahexaenoic acid in the risk for intracranial artery stenosis. Atherosclerosis 2012, 225(2):418-424.
47. Kasner S.E., Chimowitz M.I., Lynn M.J., et al. For the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006, 113:555-563.
48. Layé S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins, Leukot Essent Fatty Acids 2010, 82:295-303.
49. Akbar M., Calderon F., Wen Z., Kim H.-Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. PNAS 2005, 102:10858-10863.
50. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
51. Kalmijn S., Launer L.J., Ott A., Witteman J.C.M., Hofman A., Breteler M.M.B. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997, 42:776-782.
52. Schaefer E.J., Bongard V., Beiser A.S., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease. The Framingham Heart Study. Arch Neurol 2006, 63:1545-1550.
53. Morris M.C., Evans D.A., Tangney C.C., Bienias J.L., Wilson R.S. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005, 62:1849-1853.
54. Freund-Levi Y., Eriksdotter-Jönhagen M., Cederholm T., et al. ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study. A randomized double-blind trial. Arch Neurol 2006, 63:1402-1408.
55. Freund-Levi Y., Basun H., Cederholm T., et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008, 23:161-169.
56. Siegel G, Malmsten M. Molecular model for athero/arteriosclerosis. Patent EP 0 946 876; 2005.
57. Siegel G., Abletshauser C., Malmsten M., Schmidt A., Winkler K. Reduction of arteriosclerotic nanoplaque formation and size by fluvastatin in a receptor-based biosensor model. Cardiovasc Res 2003, 58:696-705.
58. Rodríguez M., Ringstad L., Schäfer P., et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis 2007, 192:438-444.
59. Siegel G., Rodríguez M., Sauer F., et al. Nanotechnologic biosensor ellipsometry and biomarker pattern analysis in the evaluation of atherosclerotic risk profile. Biosens Bioelectron 2009, 24:1512-1517.
60. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
61. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
62. Graff-Radford N.R., Crook J.E., Lucas J., et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007, 64:354-362.
63. Strittmatter W.J., Weisgraber K.H., Huang D.Y., et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. PNAS 1993, 90:8098-8102.
64. Sanan D.A., Weisgraber K.H., Russell S.J., et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994, 94:860-869.
65. Mahley R.W. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Isr J Med Sci 1996, 32:414-429.
66. Malmsten M., Kassner U., Winkler K., et al. An ellipsometry-based Alzheimer plaque mimic: effect of β-amyloid, lipoprotein identity and apolipoprotein E isoform. J Colloid Interface Sci 2004, 276:503-506.
67. Winkler K., Scharnagl H., Tisljar U., et al. Competition of Aβ amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J Lipid Res 1999, 40:447-455.
68. Rizos E.C., Ntzani E.E., Bika E., Kostapanos M.S., Elisaf M.S. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events. A systematic review and meta-analysis. JAMA 2012, 308:1024-1033.